>
Switch to:

Regeneron Pharmaceuticals ROE %

: 40.32% (As of Sep. 2021)
View and export this data going back to 1991. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Regeneron Pharmaceuticals's annualized net income attributable to common stockholders for the quarter that ended in Sep. 2021 was $6,529 Mil. Regeneron Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Sep. 2021 was $16,193 Mil. Therefore, Regeneron Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2021 was 40.32%.

The historical rank and industry rank for Regeneron Pharmaceuticals's ROE % or its related term are showing as below:

NAS:REGN' s ROE % Range Over the Past 10 Years
Min: -43.76   Med: 22.37   Max: 86.68
Current: 53.39

-43.76
86.68

During the past 13 years, Regeneron Pharmaceuticals's highest ROE % was 86.68%. The lowest was -43.76%. And the median was 22.37%.

NAS:REGN's ROE % is ranked higher than
97% of the 1341 Companies
in the Biotechnology industry.

( Industry Median: -38.75 vs. NAS:REGN: 53.39 )

Regeneron Pharmaceuticals ROE % Historical Data

The historical data trend for Regeneron Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.10 22.63 32.81 21.32 31.77

Regeneron Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.12 43.47 38.79 91.47 40.32

Competitive Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Regeneron Pharmaceuticals ROE % Distribution

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's ROE % falls into.



Regeneron Pharmaceuticals ROE % Calculation

Regeneron Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=3513.2/( (11089.7+11025.3)/ 2 )
=3513.2/11057.5
=31.77 %

Regeneron Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Sep. 2021 )/( (Total Stockholders Equity (Q: Jun. 2021 )+Total Stockholders Equity (Q: Sep. 2021 ))/ count )
=6528.8/( (15127.3+17258)/ 2 )
=6528.8/16192.65
=40.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Sep. 2021) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Regeneron Pharmaceuticals  (NAS:REGN) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Sep. 2021 )
=Net Income/Total Stockholders Equity
=6528.8/16192.65
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(6528.8 / 13811.2)*(13811.2 / 22578.7)*(22578.7 / 16192.65)
=Net Margin %*Asset Turnover*Equity Multiplier
=47.27 %*0.6117*1.3944
=ROA %*Equity Multiplier
=28.92 %*1.3944
=40.32 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Sep. 2021 )
=Net Income/Total Stockholders Equity
=6528.8/16192.65
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (6528.8 / 7266.4) * (7266.4 / 7388.8) * (7388.8 / 13811.2) * (13811.2 / 22578.7) * (22578.7 / 16192.65)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8985 * 0.9834 * 53.5 % * 0.6117 * 1.3944
=40.32 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Sep. 2021) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Sep. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Regeneron Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Regeneron Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
Executives
Goldstein Joseph L director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS 5323 HARRY HINES BLVD DALLAS TX 75390
Ryan Arthur F director CITIZENS FINANCIAL GROUP, INC 600 WASHINGTON BOULEVARD STAMFORD CT 06901
Brown Michael S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: BROWN MICHAEL S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Sing George L director LANCET CAPITAL 45 ROCKEFELLER PLAZA STE 2008 NEW YORK NY 10111
Poon Christine A director C/O JOHNSON & JOHNSON ONE JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Larosa Joseph J officer: EVP General Counsel and Secret 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Mccourt Marion officer: SVP Commercial C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Vagelos P Roy director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: VAGELOS P ROY a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Landry Robert E officer: EVP Finance CFO 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Fenimore Christopher R. officer: VP Controller REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Murphy Andrew J officer: EVP Research REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Zoghbi Huda Y director REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Bassler Bonnie L director REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Sanofi 10 percent owner 54 RUE LA BOETIE PARIS I0 75008

Regeneron Pharmaceuticals Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)